CAS 88930-15-8|Mogrol
Introduction：Basic information about CAS 88930-15-8|Mogrol, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Mogrol | ||
|---|---|---|---|
| CAS Number | 88930-15-8 | Molecular Weight | 476.732 |
| Density | 1.1±0.1 g/cm3 | Boiling Point | 595.6±50.0 °C at 760 mmHg |
| Molecular Formula | C30H52O4 | Melting Point | / |
| MSDS | / | Flash Point | 242.9±24.7 °C |
Names
| Name | Mogrol |
|---|---|
| Synonym | More Synonyms |
Mogrol BiologicalActivity
| Description | Mogrol is a biometabolite of mogrosides, and acts via inhibition of the ERK1/2 and STAT3 pathways, or reducing CREB activation and activating AMPK signaling. |
|---|---|
| Related Catalog | Signaling Pathways >>MAPK/ERK Pathway >>ERKSignaling Pathways >>Stem Cell/Wnt >>ERKResearch Areas >>CancerNatural Products >>Terpenoids and Glycosides |
| Target | ERK1 ERK2 STAT3 |
| In Vitro | Mogrol (0-250 µM) significantly and dose- and time-dependently inhibits K562 cell growth and increases the number of apoptotic cells. Mogrol (0, 10, 100, and 250 µM) induces G1 phase cell cycle arrest in K562 cells. Treatment with mogrol significantly decreases ERK phosphorylation as compared to control cells, whereas total ERK protein is not affected. Mogrol dose-dependently induces growth arrest in G0/G1 phase of the cell cycle. Mogrol significantly and dose-dependently enhances p21 protein expression in K562 cells[1]. Mogrol significantly represses the increase in cellular TG levels induced by differentiation stimuli, and suppresses TG accumulation at micromolar levels, with a statistically significant suppression observed above 10 μM. Mogrol suppresses adipogenesis in 3T3-L1 cells at concentrations that does not affect cell viability. Mogrol suppresses adipogenesis through at least two different mechanisms, increasing AMPK phosphorylation and repressing the activation of CREB[2]. |
| Cell Assay | Cell viability is determined with a MTT assay. Leukemia cells are plated in triplicate into a 96-well plate. After overnight incubation, they are treated with various concentrations of mogrol (0, 0.1, 1, 10, 100, 200 and 250 µM) for 24 h and 48 h. The percentage of viable cells is calculated as the ratio (A490) of treated cells over control cells. Triplicate experiments are performed. |
| References | [1]. Liu C, et al. Mogrol represents a novel leukemia therapeutic, via ERK and STAT3 inhibition. Am J Cancer Res. 2015 Mar 15;5(4):1308-18. [2]. Naoki Harada, et al. Mogrol Derived from Siraitia grosvenorii Mogrosides Suppresses 3T3-L1 Adipocyte Differentiation by Reducing cAMP-Response Element-Binding Protein Phosphorylation and Increasing AMP-Activated Protein Kinase Phosphorylation. PLoS One. 2 |
Chemical & Physical Properties
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 595.6±50.0 °C at 760 mmHg |
| Molecular Formula | C30H52O4 |
| Molecular Weight | 476.732 |
| Flash Point | 242.9±24.7 °C |
| Exact Mass | 476.386566 |
| LogP | 5.49 |
| Vapour Pressure | 0.0±3.8 mmHg at 25°C |
| Index of Refraction | 1.553 |
| InChIKey | JLYBBRAAICDTIS-AYEHCKLZSA-N |
| SMILES | CC(CCC(O)C(C)(C)O)C1CCC2(C)C3CC=C4C(CCC(O)C4(C)C)C3(C)C(O)CC12C |
| Storage condition | -20°C |
Synonyms
| Estr-5-ene-3,11-diol, 17-[(1R,4R)-4,5-dihydroxy-1,5-dimethylhexyl]-4,4,9,14-tetramethyl-, (3β,9β,10α,11α,17β)- |
| (1S,4R,9β,11α,24R)-9,10,14-Trimethyl-4,9-cyclo-9,10-secocholest-5-ene-1,11,24,25-tetrol |
